About
Company
Allotera is a pivotal-stage biotechnology company advancing next generation off-the-shelf therapies
OPTIMIZED BY EVOLUTION
Our allogeneic therapies are derived from healthy donor cells and are engineered to deliver robust anti-tumor activity.
With our proprietary CAR-T platform, Allotera is addressing critical unmet needs in hematologic malignancies.
Our US-based manufacturing is optimized for scale, consistency, and rapid deployment, enabling the delivery of transformative therapies to patients with speed and precision.